Research programme - cancer therapeutics - Eureka Therapeutics

Drug Profile

Research programme - cancer therapeutics - Eureka Therapeutics

Alternative Names: ET 1402; ET 1402L1; ET 1501; ET 1502; ET 1504; TCR mimic antibody therapeutics - Eureka Therapeutics; TCRm antibody therapeutics - Eureka Therapeutics

Latest Information Update: 20 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eureka Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; Monoclonal antibodies; T lymphocyte cell therapies
  • Mechanism of Action Immunomodulators; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological malignancies; Liver cancer
  • Research Cervical cancer; Head and neck cancer; Lung cancer; Prostate cancer

Most Recent Events

  • 03 Dec 2016 Pharmacodynamics data from a preclinical trial in Haematological malignancies presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 01 Feb 2016 Early research in Cervical cancer in USA (Parenteral) prior to February 2016 (Eureka Therapeutics pipeline, February 2016)
  • 01 Feb 2016 Early research in Head and neck cancer in USA (Parenteral) prior to February 2016 (Eureka Therapeutics pipeline, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top